



BIODIEM LTD
ABN 20 096 845 993
Level 4,
100 Albert Rd,
South Melbourne, Victoria, 3205
Australia
Phone: +613 9692 7240
Web: www.biodiem.com

Announcement

New European patents for Opal Biosciences antimicrobial, BDM-I

Melbourne, 6 November 2015: BioDiem Ltd is pleased to announce that the European patent office has granted two new divisional patents for BDM-I use in two areas of infection:

- Enteric or gut infections caused by the bacteria *Clostridium perfringens*, *Clostridium difficile*, *Salmonella typhimurium*, *Salmonella paratyphi*, *Campylobacter*, *Shigella* variant spp., *Bacteroides* and *Bacillus subtilis*; and the yeast, *Candida albicans*; and
- Other infections such as systemic and respiratory infections caused by many bacteria including methicillin-resistant *Staph aureus* (Golden Staph) and *Strep pyogenes*, *Strep epidermidis*, *Haemophilus influenza* which can cause serious infections.

Julie Phillips, CEO, Biodiem Ltd, commented "The grant of these patents covers a broad range of disease-causing microbes for which new treatment are important. They add to claim coverage in Europe which already has been granted for germs causing infection of the female urogenital tract and also protozoal infections; and to those already covered in the major global markets of Japan, China and the US."

BioDiem's subsidiary, Opal Biosciences Ltd is conducting a capital-raising to continue the development of

- an injectable product, Opal-I, which will be targeted to the treatment of serious infections including those which are antibiotic-resistant; and
- a treatment for the skin, Opal-T, for superficial infections.

BDM-I is also currently in US programs for drug-resistant tuberculosis (TB), the fungal infection caused by *Pneumocystis*, and a biowarfare agent.

- ENDS -

About BioDiem Ltd

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising

vaccines and infectious disease therapies. BioDiem's business model is to generate income from partnerships including with other vaccine and infectious disease treatment companies through existing and new licences to its LAIV vaccine and other technologies. Income comes from licence fees and royalties on sales.

BioDiem's lead technology is the LAIV (Live Attenuated Influenza Virus) vaccine technology used for production of seasonal and pandemic influenza vaccines and is given intranasally. This technology is licensed currently to two commercial partners, in India and China, and is licenced to the World Health Organisation as part of the Global Pandemic Influenza Action Plan to Increase Vaccine Supply. Serum Institute of India's Nasovac-S™ is based on BioDiem's technology and is already marketed in India.

BioDiem's antimicrobial technology, BDM-I, is being developed through its subsidiary, Opal Biosciences Ltd. For additional information, please visit www.biodiem.com.

About Opal Biosciences Ltd

Opal Biosciences is an Australian biotechnology company and an innovative player in infectious disease treatment. The unmet need for new anti-infectives is due to increasing resistance to existing antibiotics, more widespread and common difficult-to-treat infections, and the paucity of upcoming new treatments. This need has spurred the EU and US to introduce significant financial incentives to encourage development of new anti-infectives. Opal is currently seeking funding to support the next stage of development of our products:

- Opal-I, an injectable product, and
- Opal-T, which can be applied to the skin.

For more information, please visit www.opalbiosciences.com.